Malignant intracranial germinoma in smith-lemli-opitz syndrome: Cholesterol homeostasis possibly connecting morphogenesis and cancer development

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 9, 2008, Pages 689-691

  Oslejskova, Hana ^a   Horinova, Vera ^a   Sterba, Jaroslav ^b   Pavelka, Zdenek ^b   Babovic Vuksanovic, Dusica ^c   Dubska, Lenka ^a   Valik, Dalibor ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c Mayo Clinic   (United States)

Author keywords

Cancer genetics; CNS tumors; Germ cell tumors; Gorlin syndrome

Indexed keywords

ANGIOGENESIS INHIBITOR; CHOLESTEROL; DESMOPRESSIN; HYDROCORTISONE; LEVOTHYROXINE;

ADOLESCENT; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; GERM CELL TUMOR; HORMONE SUBSTITUTION; HUMAN; INTRACRANIAL TUMOR; MALE; PRIORITY JOURNAL; SMITH LEMLI OPITZ SYNDROME;

ADOLESCENT; BRAIN NEOPLASMS; CHOLESTEROL; DEHYDROCHOLESTEROLS; DISEASE PROGRESSION; FATAL OUTCOME; GERMINOMA; HEDGEHOG PROTEINS; HOMEOSTASIS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MORPHOGENESIS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; SMITH-LEMLI-OPITZ SYNDROME;

EID: 66249128254     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318180bbde     Document Type: Article

References (15)

1. Herman GE. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum Mol Genet. 2003;12: R75-R88.
2. Babovic-Vuksanovic D, Jacobson RM, Lindor NM, et al. Selective antibody immune deficiency in a patient with Smith-Lemli-Opitz syndrome. J Inherit Metab Dis. 2005;28:181-186.
3. Caruso PA, Poussaint TY, Tzika AA, et al. MRI and 1H MRS findings in Smith-Lemli-Opitz syndrome. Neuroradiology. 2004; 46:3-14.
4. Kelley RI, Hennekam RC. The Smith-Lemli-Opitz syndrome. J Med Genet. 2000;37:321-335.
5. Ryan AK, Bartlett K, Clayton P, et al. Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet. 1998;35:558-565.
6. Tint GS, Salen G, Batta AK, et al. Correlation of severity and outcome with plasma sterol levels in variants of the Smith-LemliOpitz syndrome. J Pediatr. 1995;127:82-87.
7. Kelley RL, Roessler E, Hennekam RC, et al. Holoprosencephaly in RSH/Smith-Lemli-Opitz syndrome: does abnormal cholesterol metabolism affect the function of Sonic Hedgehog? Am J Med Genet. 1996;66:478-484.
8. Trasimeni G, Di Biasi C, Iannilli M, et al. MRI in Smith-Lemli-Opitz syndrome type I. Childs Nerv Syst. 1997;13:47-49.
9. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. 2006;29:308-313.
10. Porter JA, Young KE, Beachy PA. Cholesterol modification of hedgehog signaling proteins in animal development. Science. 1996; 274:255-259.
11. Tint GS, Irons M, Elias ER, et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med. 1994;330:107-113.
12. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846-851.
13. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6:530-539.
14. Bijlsma MF, Spek CA, Zivkovic D, et al. Repression of smoothened by patched-dependent (pro-) vitamin D3 secretion. PLoS Biol. 2006;4:e232.
15. Shu Q, Antalffy B, Su JM, et al. Valproic acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res. 2006;12: 4687-4694.